Literature DB >> 28242094

Amicrobial pustulosis of the folds: Where have we gone 25years after its original description?

C Schissler1, C Velter1, D Lipsker2.   

Abstract

BACKGROUND: Twenty-five years ago at the Journées Dermatologiques de Paris, Prof. Béatrice Crickx described a new association, "antimicrobial pustulosis and systemic lupus erythematosus", a condition now known as amicrobial pustulosis of the folds (APF). The aim of this study is to analyse the clinical and laboratory characteristics of APF and to outline the gradual advancement of knowledge regarding this disease.
MATERIALS AND METHODS: Based on a case of APF seen in our department, we carried out a review of the literature since 1991 by searching the Medline database for scientific articles using the following keywords: "Amicrobial Pustulosis" or "Pustular Dermatosis" and "Folds".
RESULTS: We collated 63 cases of APF. In total, 90% involved women and the mean age was 30 years. Cutaneous lesions consisted of pustules in an erythematous setting, frequently erosive and affecting the skinfolds, anogenital region, scalp, external auditory meatus and umbilicus. Histological examination revealed spongiform subcorneal pustulosis associated with mixed inflammatory infiltrate in the dermis. DISCUSSION: APF belongs to the spectrum of neutrophilic dermatoses. Its complex physiopathology involves an auto-inflammatory mechanism. It is associated with a variety of autoimmune diseases, in most cases systemic lupus erythematosus. Diagnosis of the condition is difficult and is based on histological correlation and negative microbiological culture. The most effective treatment is still systemic corticosteroids, although new therapeutic alternatives are emerging such as anakinra and anti-TNF-alpha drugs.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Amicrobial pustulosis of the folds; Aseptic pustulosis; Auto-inflammatory disease; Dermatose neutrophilique; Lupus erythematosus; Lupus érythémateux; Maladie auto-inflammatoire; Neutrophil dermatosis; Pustulose amicrobienne des plis; Pustulose aseptique

Mesh:

Substances:

Year:  2017        PMID: 28242094     DOI: 10.1016/j.annder.2016.10.018

Source DB:  PubMed          Journal:  Ann Dermatol Venereol        ISSN: 0151-9638            Impact factor:   0.777


  3 in total

1.  Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT).

Authors:  S Cro; V R Cornelius; A E Pink; R Wilson; A Pushpa-Rajah; P Patel; A Abdul-Wahab; S August; J Azad; G Becher; A Chapman; G Dunnil; A D Ferguson; A Fogo; S A Ghaffar; J R Ingram; S Kavakleiva; E Ladoyanni; J A Leman; A E Macbeth; A Makrygeoegou; R Parslew; A J Ryan; A Sharma; A R Shipman; C Sinclair; R Wachsmuth; R T Woolf; A Wright; H McAteer; J N W N Barker; A D Burden; C E M Griffiths; N J Reynolds; R B Warren; H J Lachmann; F Capon; C H Smith
Journal:  Br J Dermatol       Date:  2021-08-19       Impact factor: 11.113

2.  Demodicosis as treatment complication of amicrobial pustulosis of the folds.

Authors:  Marilia Formentini Scotton Jorge; Lívia Maria Zanardi Miguel; Cíntia Santos Braghiroli; Juliano Vilaverde Schmitt
Journal:  An Bras Dermatol       Date:  2018 Jul-Aug       Impact factor: 1.896

3.  Two case reports of pyoderma gangrenosum and systemic lupus erythematosus: A rare but nonfortuitous association?

Authors:  Delphine Lebrun; Ailsa Robbins; Maxime Hentzien; Ségolène Toquet; Julie Plee; Anne Durlach; Jean-David Bouaziz; Firouzé Bani-Sadr; Amélie Servettaz
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.